The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial).
Ursula Matulonis
Consultant or Advisory Role - Tesaro
Sven Mahner
Other Remuneration - Tesaro
Robert Michael Wenham
Consultant or Advisory Role - Tesaro
Research Funding - Merck
Other Remuneration - Tesaro
Jonathan A. Ledermann
No relevant relationships to disclose
Bradley J. Monk
Consultant or Advisory Role - Tesaro
Jose Maria Del Campo
No relevant relationships to disclose
Jonathan S. Berek
Research Funding - Tesaro
Ignace Vergote
No relevant relationships to disclose
Michel Fabbro
No relevant relationships to disclose
Dionyssios Katsaros
No relevant relationships to disclose
Christian Marth
No relevant relationships to disclose
Domenica Lorusso
Consultant or Advisory Role - Janssen-Cilag; Roche
Research Funding - PharmaMar
Jorn Herrstedt
No relevant relationships to disclose
Shefali Agarwal
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Robert E. Martell
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Mansoor Raza Mirza
No relevant relationships to disclose